Universe Pharmaceuticals INC (UPC) stock
Close on Nov 13, 2026Market cap $850.64KP/E –Yield –
Universe Pharmaceuticals INC saw revenue fall 22.4% to $17.86B over fiscal 2025. Free cash flow was -$5.32B. At the latest close the market valued the company at $850.64K.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Mar 31, 2026
Valuation
- Market cap
- $850.64K
- P/E ratio
- –
- Price to sales
- 0.00
- Price to book
- 0.02
- Dividend yield
- –
- Free cash flow yield
- -625304.00%
Fundamentals
- Revenue
- $17.86B
- Net income
- -$3.67B
- EPS, diluted
- -$8.06
- Free cash flow
- -$5.32B
Trading
- Previous close
- $1.53
- Open
- $1.48
- Day's range
- $1.47 – $1.58
- Volume
- 13,050
- Average volume (20 days)
- 189,399
- Beta (5 years)
- 1.06
- 52-week range
- $1.33 – $17.96
- RSI (14 days)
- 26.9
- Volatility (1 year)
- 352.3%
- Relative volume
- 0.02×
- WACC
- 11.8%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | UPC | S&P 500 | Difference | UPC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -64.6% | -3.0% | −61.6 pts | ||
| 3 months | -74.3% | -2.8% | −71.5 pts | ||
| Year to date | -60.4% | +11.5% | −71.9 pts | ||
| 1 year | -59.6% | +13.5% | −73.1 pts | ||
| 3 years | -99.8% | +77.7% | −177.5 pts | -86.6% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -82.2% | +11.5% |
Eight years at a glance
Fiscal years 2018 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Universe Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Universe Pharmaceuticals
Pharmaceutical Preparations
Universe Pharmaceuticals INC is a Cayman Islands holding company that operates through its subsidiaries in China, primarily Jiangxi Universe Pharmaceuticals Co., Ltd. and its operating entities. The company engages in the traditional Chinese medicine (TCM) and traditional Chinese medicine derivatives (TCMD) business sectors, with dedicated research and commercial trading arms such as Guangzhou Universe Hanhe Medical Research Co., Ltd. and Jiangxi Universe Pharmaceuticals Trade Co., Ltd.
Company profile, executives and historyUniverse Pharmaceuticals stock: common questions
What is Universe Pharmaceuticals's stock price?
UPC closed at $1.51 on Nov 13, 2026, down 1.31% on the day. Over the past 52 weeks it traded between $1.33 and $17.96.
What is Universe Pharmaceuticals's market cap?
Universe Pharmaceuticals was worth $850.64K at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is UPC's P/E ratio?
Universe Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$8.06), so it has no meaningful P/E ratio.
How much revenue does Universe Pharmaceuticals make?
Universe Pharmaceuticals reported revenue of $17.86B for fiscal 2025, down 22.4% from a year earlier.
Does Universe Pharmaceuticals pay a dividend?
No. Universe Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has UPC stock performed over the past year?
Including dividends, UPC returned -59.6% over the past year, against +13.5% for the S&P 500.
Who are Universe Pharmaceuticals's competitors?
Companies most similar to Universe Pharmaceuticals by business, industry and size include VTRS, TEVA, REGN, VRTX, BHC.
See a number that looks wrong?